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doi:10.1Objective: The inhibition of adenosine deaminasewith erythro-9 (2-hydroxy-3-nonyl)-adenine (EHNA) and the
es-ENT1 transporter with p-nitro-benzylthioinosine (NBMPR), entraps myocardial intracellular adenosine dur-
ing on-pump warm aortic crossclamping, leading to a complete recovery of cardiac function and adenosine tri-
phosphate (ATP) during reperfusion. The differential role of entrapped intracellular and circulating adenosine in
EHNA/NBMPR-mediated protection is unknown. Selective (8-cyclopentyl-1,3-dipropyl-xanthine) or nonselec-
tive [8-(p-sulfophenyl)theophyline] A1 receptor antagonists were used to block adenosine A1-receptor contri-
bution in EHNA/NBMPR-mediated cardiac recovery.
Methods: Anesthetized dogs (n¼ 45), instrumented to measure heart performance using sonomicrometry, were
subjected to 30minutes of warm aortic crossclamping and 60minutes of reperfusion. Three boluses of the vehicle
(seriesA) or 100mMEHNAand25mMNBMPR (seriesB)were infused into the pump at baseline, before ischemia
and before reperfusion. 8-Cyclopentyl-1,3-dipropyl-xanthine (10 mM) or 8-(p-sulfophenyl)theophyline (100 mM)
was intra-aortically infused immediately after aortic crossclamping distal to the clamp in seriesA and series B. The
ATP pool and nicotinamide adenine dinucleotidewas determined using high-performance liquid chromatography.
Results: Ischemia depleted ATP in all groups by 50%. The adenosine/inosine ratios were more than 10-fold
greater in series B than in series A (P<.001). ATP and function recovered in the EHNA/NBMPR-treated group
(P<.05 vs control group). 8-Cyclopentyl-1,3-dipropyl-xanthine and 8-(p-sulfophenyl)theophyline partially re-
duced cardiac function in series A and B to the same degree but did not abolish the EHNA/NBMPR-mediated
protection in series B.
Conclusions: In addition to the cardioprotection mediated by activation of the adenosine receptors by extracel-
lular adenosine, EHNA/NBMPR entrapment of intracellular adenosine provided a significant component of
myocardial protection despite adenosine A1 receptor blockade. (J Thorac Cardiovasc Surg 2012;144:243-9)Supplemental material is available online.
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Spostischemic reperfusion injury3 is critical for improving
intra- and postoperative outcomes. Adenosine has emerged
as a promising adjuvant agent to augment cardioprotection
in experimental models4-6 and clinical trials7-10 against
ischemic and reperfusion injury. Blockade of the
adenosine A1 receptor abolishes the cardioprotection
mediated by ischemic preconditioning,4 and treatment
with exogenous adenosine potentiates ischemic precondi-
tioning effects.6 Unlike exogenous adenosine, endogenous
adenosine generated during ischemia must be transported
by way of the p-nitro-benzylthioinosine (NBMPR)-sensi-
tive es-ENT1 transporter 1 (es-ENT1) to the extracellular
domain (Figure E1, A) to activate the adenosine receptor
subtype (A1, A2A, A2B, and A3)-mediated signaling
mechanisms of cardioprotection. Because of the short half
life of adenosine in humans and animals, inhibition of aden-
osine deaminase by erythro-9 (2-hydroxy-3-nonyl)-adenine
(EHNA) prolongs its half life and potentiates its pharmaco-
logic efficacy. In addition, selective blockade of es-ENT1
with NBMPR entraps myocardial adenosine and inosinerdiovascular Surgery c Volume 144, Number 1 243
Abbreviations and Acronyms
ATP ¼ adenosine triphosphate
DPCPX ¼ 8-cyclopentyl-1,3-dipropyl-xanthine
EHNA ¼ erythro-9 (2-hydroxy-3-nonyl)-
adenine
NBMPR ¼ p-nitro-benzylthioinosine
SPT ¼ 8-(p-sulfophenyl)theophyline
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Sat the site of production during ischemia and prevents its
loss during reperfusion. Preischemic treatment with
EHNA/NBMPR entraps intracellular adenosine and
results in complete recovery of adenosine triphosphate
(ATP) and cardiac function,11-13 suggesting that the
entrapped adenosine is intracellularly compartmentalized
(Figure E1, B). The specific binding sites of [3H]-NBMPR
were identified in human and animal myocardial prepara-
tions.14 The relative contribution of entrapped intracellular
adenosine and circulating extracellular adenosine in
EHNA/NBMPR-mediated protection in relation to adeno-
sine A1 receptor activation (Figure E1, C) is not known.
The present study was designed to determine the role of
the adenosine A1 receptor in EHNA/NBMPR-mediated
postischemic recovery of function in a canine model of
on-pump warm aortic crossclamping (ACC) and reperfu-
sion. Selective blocking of the adenosine A1 receptor
with 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX) or
nonselective blocking of adenosine receptor subtypes with
8-(p-sulfophenyl)theophyline (SPT) partially reduces but
does not abolish postischemic recovery mediated by
EHNA/NBMPR, suggesting intracellular mechanisms of
protection.METHODS
Materials
The biochemical reagents, EHNA and NBMPR, were purchased from
Sigma-Aldrich (St. Louis, Mo), and DPCPX and SPT were purchased
from Research Biochemical (Natick, Mass).
Animal Model
The experiments conformed to the Guidelines for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(publication no. 5377-3; available at: http://www.nap.edu/catalog/5140.
html).
A total of 45 microfilaria-free adult mongrel dogs, of either sex, weigh-
ing 17 to 25 kg were used in the present study. The dogs were initially anes-
thetized with 35 mg/kg intravenous sodium pentobarbital (Nembutal;
Abbott Laboratories, Chicago, Ill). The surgical procedures and instrumen-
tations were performed exactly as described previously.11 Cardiopulmo-
nary bypass was established by subclavian artery and atrial venous
cannulation. A membrane oxygenator (Medtronic, Minneapolis, Minn)
was used and primed with noncross-matched homologous blood. The
mean arterial reperfusion pressure was maintained at 60 to 65 mm Hg dur-
ing bypass. Arterial blood gases, pH, and hematocrit were routinely deter-
mined and maintained at the following levels: oxygen partial pressure, 100244 The Journal of Thoracic and Cardiovascular Surgto 140 mm Hg; carbon dioxide partial pressure, 30 to 40 mm Hg, pH, 7.32
to 7.48; and hematocrit, about 30%.
Assessment of Left Ventricular Performance
Left ventricular (LV) performance was assessed, off the bypass pump,
from the relationship between stroke work and the end-diastolic dimension
using a sensitive and load-independent index of contractility,11 pulse transit
sonomicrometry (Triton Technology, San Diego, Calif), and Millar
pressure transducers. One pair of lead titanate zirconate piezoelectric hemi-
spheric crystals was sutured to the anterior and posterior of the epicardial
surface of the left ventricle wall in the minor axis (40–60mm). Analog data
were digitized at 200 Hz and stored on a personal computer hard disc and
analyzed using interactive Crunch software developed in our laboratory.
Data acquisition was performed at varying preloads by way of venous
drainage, creating diminishing work loops. The slope was obtained from
the relationship between the LV pressures (a surrogate of volume) against
the end-diastolic lengths and is considered as a sensitive load-independent
index of contractility.
Assessment of Adenine Nucleotide Pool Metabolism
Transmural serial Tru-Cut needle biopsy specimens (5–10 mg) were ob-
tained and immediately frozen in liquid nitrogen (196C), extracted, ana-
lyzed, and quantified using high-performance liquid chromatography, and
presented as nmoles/mg protein.11
Experimental Protocol
After a 30-minute stabilization period on pump, the dogs were assigned
1 of 2 series: A or B. Three boluses (500 mL each) of the vehicle solution
(saline containing 0.05% dimethylsulfoxide) without (series A) or with
(series B) 25 mM NBMPR and 100 mM EHNA, were infused into the
pump oxygenator before ischemia, before ACC, and just before releasing
ACC. The dogs in series A received a single intra-aortic infusion of 50
mL of saline (control group, n ¼ 10), 100 mM SPT (n ¼ 6) or 10 mM
DPCPX (n ¼ 7) distal to the clamp immediately after ACC. In series B,
the dogs were treated with a single intra-aortic infusion of 50 mL of vehicle
(EHNA/NBMPR group, n ¼ 8), 100 mM SPT (n ¼ 7) or 10 mM DPCPX
(n ¼ 7).
Statistical Analysis
The data are presented as the mean  standard error of the mean. Se-
quential measurements were compared using repeated measures analysis
of variance and Tukey’s post hoc tests using SAS (SAS Institute, Cary,
NC). Differences were considered significant if the probability value for
the comparison of the least squares mean was less than .05; the F ratios
are provided with the figures.
RESULTS
The results of the control group and EHNA/NBMPR-
treated group have been previously published9,10 and are
included in the present report for comparison. This model
represents a scenario of reversible global myocardial
stunning without necrosis, and all dogs survived for the
length of the experiments in all groups.
Myocardial ATP
On-pump normothermic ACC for 30 minutes reduced
the myocardial ATP levels by about 50% in all groups
(Figure 1). No recovery of ATP was observed in the series
A groups during reperfusion. In series B, ATP had recovered
at the end of reperfusion in the EHNA/NBMPR-treatedery c July 2012
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FIGURE 1. Effect of 8-(p-sulfophenyl)theophyline (SPT) and 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX) onmyocardial adenosine triphosphate (ATP)
levels. ATP was measured in myocardial biopsies before and after saline (control) or drug administration and at the end of ischemia and during reperfusion.
No significant differences between groups were seen with respect to the time of sampling (analysis of variance, F ¼ 0.04). *Statistically significant versus
baseline. E/N, ENHA/NBMPR; ENHA, erythro-9 (2-hydroxy-3-nonyl)-adenine; NBMPR, p-nitro-benzylthioinosine.
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Sgroup (25.98  0.8 nmol/mg protein vs baseline 28.41 
2.3 nmol/mg protein; P ¼ NS). The ATP levels increased
in the SPT-treated group in the presence of EHNA/NBMPR
to 22.2  2.2 nmol/mg protein. ATP remained depressed in
the DPCPX groups in both series A and B (18.4  2.6 and
17.30  2.2 nmol/mg protein, respectively; P < .05 vs
baseline).
Myocardial Adenine Nucleosides
Neither adenosine nor inosine was detected before or af-
ter EHNA/NBMPR treatment on pump. A small increase in
myocardial adenosine occurred at the end of ischemia in the
control group (0.8  0.1 nmol/mg protein). Inosine was the
major (>90%) nucleoside present in the control, SPT-, and
DPCPX-treated groups of series A at the end of ischemia
(Figure 2, B). The adenosine and inosine generated during
ischemia both disappeared from the myocardium during re-
perfusion in all groups of series A (Figure 2, A). Myocardial
adenosine increased in the EHNA/NBMPR groups (series
B) during ischemia as follows: 11.15  0.7, 16.39  1.6,
and 14.44  0.9 nmol/mg protein in the vehicle, SPT, and
DPCPX groups, respectively (P<.05 vs baseline and series
A groups). The inosine levels in the series B groups were
also elevated (1.40  0.4, 1.49  0.2, and 0.55  0.2
nmol/mg protein at the end of the ischemic period in the
presence of vehicle, SPT, and DPCPX, respectively;
P<.05 vs baseline and series A). During reperfusion, the
ischemic myocardium lost all its adenosine and inosine in
the series A groups but retained them in the series B groups
(P>.05 vs baseline and series A groups).
LV Performance
Administration of the vehicle solution or EHNA/
NBMPR did not affect LV contractility before ischemiaThe Journal of Thoracic and Ca(Figure 3, A). In series A, LV function in the control group
recovered to only 55% and 71.6% of preischemic function
(44.27  6.7 dyn/cm2 3 103 and 57.58  6.1 dyn/
cm2 3 103) after 30 and 60 minutes of reperfusion, respec-
tively (baseline, 80.42  8.1 dyn/cm23 103; P<.05). SPT
significantly reduced cardiac function in series A to less
than the control level by 36.7% and 27.2% at 30 and 60
minutes of reperfusion, respectively (P<.05 vs before is-
chemia, 75.73  4.3 dyn/cm2 3 103). In the presence of
DPCPX, LV function had also declined at 30 and 60 min-
utes of reperfusion to 40.37% and 43.21%, respectively
(before ischemia, 84.65  8.9 dyn/cm2 3 103; P< .05).
In the EHNA/NBMPR group, the LV function returned
to 99.42% and 119.34% of the preischemic value after
30 and 60 minutes of reperfusion, respectively (before is-
chemia, 72.4  5.9 dyn/cm2 3 103; P ¼ NS). Intra-
aortic infusion of the nonselective antagonist SPT in the
presence of EHNA/NBMPR (series B) resulted in a signif-
icant decline in postischemic recovery to 54.03% and
57.99% of preischemic function (39.5  6.6 and 42.4 
6 dyn/cm2 3 103) after 30 and 60 minutes of reperfusion,
respectively (baseline, 73.1  4.2 dyn/cm23 103; P<.05).
DPCPX administration in the EHNA/NBMPR-treated
groups resulted in a modest decline in LV functional recov-
ery after global ischemia to 68.23% and 76.06% of prei-
schemic function (54.7  9 and 60.9  7 dyn/
cm2 3 103) at 30 and 60 minutes of reperfusion, respec-
tively (baseline, 80.1  8 dyn/cm2 3 103; P < .05).
When the differences between the percentage of recovery
for each corresponding antagonists were plotted for each
antagonist in the presence or absence of EHNA/NBMPR
(Figure 3, B), it was clear that the reduction in function
was identical in series A and B with respect to each
antagonist.rdiovascular Surgery c Volume 144, Number 1 245
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FIGURE 2. Effect of 8-(p-sulfophenyl)theophyline (SPT) and 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX) on myocardial adenine nucleoside levels.
Adenine nucleosides, A, adenosine and B, inosine, were measured in myocardial biopsies before and after saline (control) or drug administration and at
the end of ischemia and during reperfusion. Statistically significant differences were found between groups with respect to the time of sampling
(P<.001, analysis of variance, F ¼ 11.8 and F ¼ 8.8). *Statistically significant versus baseline. E/N, ENHA/NBMPR; ENHA, erythro-9 (2-hydroxy-
3-nonyl)-adenine; NBMPR, p-nitro-benzylthioinosine.
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SDISCUSSION
The results from previous studies,11,12 also included in
the present report, have demonstrated that selective
modulation of adenosine deamination with EHNA and
transport with NBMPR during ischemia entraps
intracellular adenosine and improves postischemic ATP
and functional recovery during reperfusion. Because
myocardial adenosine was elevated during ischemia
more than 10-fold greater in the EHNA/NBMPR-
treated groups compared with the controls, it is has
been postulated that adenosine receptor subtypes (A1,
A2A, A2B, A3) are involved in EHNA/NBMPR-
mediated postischemic recovery. Endogenous adenosine-
triggered activation of adenosine receptors is involved
in ischemic preconditioning, and DPCPX or SPT abol-
ishes the infarct size limitation mediated by ischemic
preconditioning.4-6246 The Journal of Thoracic and Cardiovascular SurgIn the present study, preischemic treatment with EHNA/
NBMPR elevated myocardial adenosine and improved
functional and ATP recovery during reperfusion in the ab-
sence or presence of adenosine A1 receptor blockade. These
results suggest that only a part of the recovery is mediated
by extracellular adenosine and activation of membrane sur-
face adenosine receptors. The remaining component of re-
covery could be mediated by intracellular adenosine and
possibly involve intracellular signaling mechanisms of pro-
tection. Grube and colleagues15 have recently shown evi-
dence for intracellular localization of the A2B adenosine
receptor in rat cardiomyocytes.
It has long been assumed that endogenous adenosine,
produced during the onset of ischemia, is derived solely
from cardiac ATP depletion. This might be true in isolated
perfused hearts or cardiomyocytes preparations. Myocar-
dial ischemia triggers sympathetic stimulation and a surgeery c July 2012
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FIGURE 3. Effect of 8-(p-sulfophenyl)theophyline (SPT) and 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX) on left ventricular (LV) performance. A, Plot
showing the slope of the relationship between the stroke work/end-diastolic dimensions of the left ventricle at each point, except during ischemic arrest.
Statistically significant differences seen between groups with respect to the time of sampling (P<.05, analysis of variance, F ¼ 4.18). *Statistically sig-
nificant versus baseline. B, Effect of SPT and DPCPX on the differences between recovery of LV performance. The differences between the percentage of
recovery were identical in series A and B, suggesting that the contribution of extracellular adenosine is identical. E/N, ENHA/NBMPR; ENHA, erythro-9
(2-hydroxy-3-nonyl)-adenine; NBMPR, p-nitro-benzylthioinosine.
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Sof co-released neurotransmitters and ATP.16-18 Similar to
cardiac adenosine, noncardiac ATP is rapidly broken
down in the circulation to adenosine, inosine,
hypoxanthine, and xanthine, providing substrates for free
radical production catalyzed by xanthine oxidase
(Figure E1). It is possible that extracellular adenosine is ac-
tivating both the DPCPX-sensitive A1 receptor and SPT-
sensitive A1, A2A, A2B, and A3 subtypes. Administration
of DPCPX or SPT abolished the contribution only of the
surface adenosine A1 receptor and other subtypes in the re-
covery of function without affecting intracellular
adenosine-mediated protection. It has been shown that
adenosine receptors cross-talk and work together in concert
to induce cardioprotection.19 Activation of A2A, A2B, and
A3 is required for A1 receptor activation.20,21 Therefore, weThe Journal of Thoracic and Capostulate that a DPCPX- or SPT-sensitive contribution in
EHNA/NBMPR-mediated recovery is occurring, regardless
of the entrapment of intracellular adenosine. The remaining
component of functional recovery could be related to
unique, yet unknown, intracellular mechanisms of
protection.
The adenosine levels were greater in the presence of
DPCPX or SPT in the EHNA/NBMPR-treated groups
than with EHNA/NBMPR alone (Figure 2, A). This could
be explained, in part, by additive inhibitory effects between
EHNA/NBMPR and SPTor DPCPX on adenosine deamina-
tion and transport. Despite the greater accumulation of
myocardial adenosine in the series B SPT and DPCPX
groups, a modest, yet significant, recovery in cardiac func-
tion and ATP repletion was observed. Again, postischemicrdiovascular Surgery c Volume 144, Number 1 247
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adenosine is compartmentalized in ischemic cells during is-
chemia and reperfusion.
The mechanisms of EHNA/NBMPR-mediated augmen-
tation of postischemic recovery could be related to prolong-
ing the half life of intracellular and extracellular adenosine;
salvaging intracellular adenosine forATP, interruption of the
formation and the release of inosine as a precursor for the
purine-free radical substrates, hypoxanthine and xanthine11;
and intracellular adenosine activates unknown intracellular
signaling mechanisms mediated by intracellular adenosine
receptor subtypes. Xia et al22 have reported that inhibition
of adenosine deaminase with EHNA (without NBMPR)
abolished the formation of free radical species after global
ischemia. In an isolated rabbit heart model, EHNA/NBMPR
abolished the ischemic preconditioning effects on infarct
size.23 Infusion of hypoxanthine and xanthine in animals
pretreated with EHNA/NBMPR diminished LV function
recovery to the control group despite entrapment of intracel-
lular adenosine.11 The latter observations implicated the
xanthine-oxidase–mediated oxygen free radical generation
in postischemic vascular injury ‘‘stunning.’’24 A cohort
study of myocardial protection with specific blockade of
the es-ENT1 demonstrated that administration of EHNA/
NBMPR after 20minutes of warmACC but before 100min-
utes of hypothermic intermittent retrograde coronary sinus
cardioplegia abolished myocardial stunning, regardless of
cardioplegic arrest and reperfusion (unpublished data).
Our results have provided evidence that, in addition to aden-
osine/adenosine receptor protective mechanisms, entrap-
ment of adenosine and inosine provides alternative (or
rather additive, if combined) cardioprotection that might
contribute to functional recovery. Our findings should be
considered in future clinical trials of adenosine and
adenosine-modulating agents to reduce the dosage and aug-
ment pharmacologic efficacy. The present results support
the concept that nucleoside entrapping is effective in atten-
uating postischemic reperfusion injury in a severe scenario
of warm global ischemia. It is anticipated that this inter-
vention would be more efficacious under intraoperative
procedures of myocardial protection. This modality has
important clinical potential to improve the clinical out-
comes of off- or on-pump cardiac surgery, especially in
sicker and elderly patients with low metabolic and con-
tractile reserves.
Study Limitations
The present study had obvious experimental model limi-
tations that must be considered, including species-, age-,
and model-related differences.
The issueof the species-dependentpresence of xanthineox-
idase remains debatable. However, it is believed that the por-
cine heart resembles the human anatomy and coronary
distribution. The doses of EHNA and NBMPR were used248 The Journal of Thoracic and Cardiovascular Surgaccording to our previous reports,3,4 which were greater than
the Ki values (0.05 nM). The dose–response relationship
was not intended in the present canine model of ACC. The
timing of the administration of vehicle and EHNA/NBMPR
was considered to target specific modulation of adenosine
metabolism and compartmentalization during global warm
ischemia and reperfusion.CONCLUSIONS
In addition to the adenosine A1 receptor- and other
subtype-mediated protective mechanisms by extracellular
adenosine, selective entrapment of intracellular adenosine
significantly improved postischemic functional and ATP re-
covery after severewarm global ischemia.Modulation of the
adenosine metabolism and compartmentalization could
serve as an important newmodality to improve intraoperative
recoveryof stunnedhearts and attenuate acute reperfusion in-
jury in the settings of thrombolytic therapy, percutaneous
coronary intervention, coronary artery bypass grafting, and
resuscitation from hemorrhagic or cardiogenic shock.References
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FIGURE E1. Adenosine triphosphate (ATP) and purine metabolism during ischemia and reperfusion. Massive ATP depletion occurs at the onset of myo-
cardial ischemia. The es-NT1 nucleoside transporter allows the release of both adenosine and inosine on reperfusion more effectively than during ischemia.
On reperfusion, nucleosides are released and converted to hypoxanthine and xanthine, both substrates of xanthine oxidase and free radical production3 and
oxidized to free radicals. A, Noncardiac ATP co-released from nerve endings with neurotransmitters is also degraded by ecto (external active site)-ATPases,
ecto-nucleotidases, and adenosine deaminae, elevating the levels of extracellular adenosine and inosine, leading to activation of adenosine A1 receptor-
mediated signaling mechanisms. B, Erythro-9 (2-hydroxy-3-nonyl)-adenine (EHNA)/p-nitro-benzylthioinosine (NBMPR) inhibits intracellular and extra-
cellular adenosine deaminase activity and blocks es-NT1 transport system, allowing intracellular accumulation of mainly adenosine during ischemia
and reperfusion, limiting hypoxanthine and xanthine formation and free radical production. C, Administration of selective or nonselective adenosine recep-
tor antagonists blocked the action of extracellular adenosine but not the action of intracellular adenosine, interrupting adenosine receptor-mediated signaling
mechanisms. ADP, Adenosine diphosphate; AMP, adenosine monophosphate; ADA, adenosine deaminase; A1R, adenosine A1 receptor; IPLase, inosine
phosphorylase; es-ENT1, es-ENT1 transporter 1.
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